121 related articles for article (PubMed ID: 16952912)
1. Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone.
McCormick DL; Johnson WD; Kozub NM; Rao KV; Lubet RA; Steele VE; Bosland MC
Carcinogenesis; 2007 Feb; 28(2):398-403. PubMed ID: 16952912
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone.
Rao KV; Johnson WD; Bosland MC; Lubet RA; Steele VE; Kelloff GJ; McCormick DL
Cancer Res; 1999 Jul; 59(13):3084-9. PubMed ID: 10397249
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat.
McCormick DL; Rao KV
Eur Urol; 1999; 35(5-6):464-7. PubMed ID: 10325506
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid.
McCormick DL; Rao KV; Steele VE; Lubet RA; Kelloff GJ; Bosland MC
Cancer Res; 1999 Feb; 59(3):521-4. PubMed ID: 9973192
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of adjuvant-induced arthritis by 16 alpha-fluoro-5-androsten-17-one.
Schwartz AG; Pashko LL
Mil Med; 2002 Feb; 167(2 Suppl):60-3. PubMed ID: 11873519
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone.
Ratko TA; Detrisac CJ; Mehta RG; Kelloff GJ; Moon RC
Cancer Res; 1991 Jan; 51(2):481-6. PubMed ID: 1824682
[TBL] [Abstract][Full Text] [Related]
7. Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies.
Christov KT; Moon RC; Lantvit DD; Boone CW; Kelloff GJ; Steele VE; Lubet RA; Pezzuto JM
Eur J Cancer; 2004 Jun; 40(9):1404-11. PubMed ID: 15177500
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one.
Ciolino HP; MacDonald CJ; Yeh GC
Cancer Res; 2002 Jul; 62(13):3685-90. PubMed ID: 12097275
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor.
McCormick DL; Johnson WD; Bosland MC; Lubet RA; Steele VE
Nutr Cancer; 2007; 57(2):184-93. PubMed ID: 17571952
[TBL] [Abstract][Full Text] [Related]
10. Null effect of dietary restriction on prostate carcinogenesis in the Wistar-Unilever rat.
McCormick DL; Johnson WD; Haryu TM; Bosland MC; Lubet RA; Steele VE
Nutr Cancer; 2007; 57(2):194-200. PubMed ID: 17571953
[TBL] [Abstract][Full Text] [Related]
11. Identification of [14C]fluasterone metabolites in urine and feces collected from dogs after subcutaneous and oral administration of [14C]fluasterone.
Burgess JP; Green JS; Hill JM; Zhan Q; Lindeblad M; Lyubimov A; Kapetanovic IM; Schwartz A; Thomas BF
Drug Metab Dispos; 2009 May; 37(5):1089-97. PubMed ID: 19196848
[TBL] [Abstract][Full Text] [Related]
12. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats.
McCormick DL; Rao KV; Dooley L; Steele VE; Lubet RA; Kelloff GJ; Bosland MC
Cancer Res; 1998 Aug; 58(15):3282-8. PubMed ID: 9699656
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one.
Perkins SN; Hursting SD; Haines DC; James SJ; Miller BJ; Phang JM
Carcinogenesis; 1997 May; 18(5):989-94. PubMed ID: 9163685
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism.
Shilkaitis A; Green A; Punj V; Steele V; Lubet R; Christov K
Breast Cancer Res; 2005; 7(6):R1132-40. PubMed ID: 16457693
[TBL] [Abstract][Full Text] [Related]
15. Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland.
McCormick DL; Rao KV; Johnson WD; Bowman-Gram TA; Steele VE; Lubet RA; Kellof GJ
Cancer Res; 1996 Apr; 56(8):1724-6. PubMed ID: 8620482
[TBL] [Abstract][Full Text] [Related]
16. High bioavailability of dehydroepiandrosterone administered percutaneously in the rat.
Labrie C; Flamand M; Bélanger A; Labrie F
J Endocrinol; 1996 Sep; 150 Suppl():S107-18. PubMed ID: 8943794
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination.
Rao CV; Tokumo K; Rigotty J; Zang E; Kelloff G; Reddy BS
Cancer Res; 1991 Sep; 51(17):4528-34. PubMed ID: 1831401
[TBL] [Abstract][Full Text] [Related]
18. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations.
Lubet RA; Gordon GB; Prough RA; Lei XD; You M; Wang Y; Grubbs CJ; Steele VE; Kelloff GJ; Thomas CF; Moon RD
Cancer Res; 1998 Mar; 58(5):921-6. PubMed ID: 9500451
[TBL] [Abstract][Full Text] [Related]
19. Novel dehydroepiandrosterone analogues with enhanced biological activity and reduced side effects in mice and rats.
Schwartz AG; Lewbart ML; Pashko LL
Cancer Res; 1988 Sep; 48(17):4817-22. PubMed ID: 2970293
[TBL] [Abstract][Full Text] [Related]
20. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
